SNTI
$0.92+0.02 (+2.14%)
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
Recent News
BC-Most Active Stocks
Nu Holdings Ltd. 29,941,575 16.73
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 6,307% surge in interest CG Oncology (CGON), 3,377% surge in interest Chemomab Therapeutics (CMMB), 3,029% surge in interest BioCardia (BCDA), 1,244% surge in interest Senti Biosciences (SNTI), 1,175% surge in interest Tevogen Bio Holdings (TVGN), 332% surge in interest Regulus Therapeutics (RGLS), 223% surge in interest Spr
Senti Biosciences Pauses Enrollment in Hepatocellular Carcinoma Trial in China; Shares Fall
Senti Biosciences (SNTI) said Monday enrollment in the investigator-sponsored trial for SENTI-301A,